par Poppe, Willy;Simon, Philippe 
;Tjalma, Wiebren Age Andries;De Ridder, Marc
Référence Current Cancer Therapy Reviews, 6, 2, page (120-125)
Publication Publié, 2010
;Tjalma, Wiebren Age Andries;De Ridder, Marc Référence Current Cancer Therapy Reviews, 6, 2, page (120-125)
Publication Publié, 2010
Article révisé par les pairs
| Résumé : | Prophyllactic HPV vaccines are efficacious in preventing persistent infections by vaccine-HPV types and re- lated cervical disease. The maximum effect is achieved in women who are not exposed to HPV vaccine types at the time of vaccination (HPV DNA negative women). Today's published data demonstrate equal clinical vaccine efficacy in women between 15 and 26 years and women between 24 and 45 years. The public health effect of vaccinating women older than 25 years is not clear yet, but may be smaller than after vaccination of adolescents. Unresolved issues are dura- tion of protection and long-term preventive effects after treatment of HPV-related disease or natural clearance of HPV in- fection. Furthermore, it remains difficult to define subgroups of older women who would benefit from the vaccine. It may be that older women exposed to HPV or who are being treated for HPV related disease will benefit most at long term. This needs longer follow-up of vaccinated women and more detailed analysis of data from vaccine trials. © 2010 Bentham Science Publishers Ltd. |
